Journal: International Journal of Molecular Sciences

Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

doi: 10.3390/ijms27114875

Figure Lengend Snippet: Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and CD45. ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed CD45 positive staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.

Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

Techniques: Negative Control, Marker, Staining, Software

Journal: International Journal of Molecular Sciences

Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

doi: 10.3390/ijms27114875

Figure Lengend Snippet: Representative images of patient-derived DTCs with three different profiles. ( A ) DTC positive for Vim, VEGF and p16, negative for CK, PD-L1 and CD45. ( B ) CK and Vim positive while negative for VEGF, PD-L1, p16 and CD45. ( C ) DTC positive for Vim and PD-L1, negative for all other markers. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and figure was assembled using Microsoft PowerPoint.

Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

Techniques: Derivative Assay, Software

Journal: International Journal of Molecular Sciences

Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

doi: 10.3390/ijms27114875

Figure Lengend Snippet: Proportion of DTC Phenotypes. The majority of detected DTCs (70%, n = 174) was positive for Vimentin without CK expression, hence revealing a mesenchymal phenotype. An epithelial phenotype was found in 13% ( n = 31) of the DTCs and 15% ( n = 37) presented epithelial–mesenchymal transition (EMT)-like properties. Chart generated using Microsoft Excel.

Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

Techniques: Expressing, Generated

Journal: International Journal of Molecular Sciences

Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

doi: 10.3390/ijms27114875

Figure Lengend Snippet: Sequential multi-parameter immunofluorescent staining. After applying the first antibody panel (CK, Vim and VEGF), the slides were scanned and DTC profiles were assessed. Subsequently, releasable fluorochrome-conjugates were digested and the slides were subjected to the second antibody panel (PD-L1, p16, CD45) followed by scanning and DTC detection. Created with BioRender.com.

Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

Techniques: Staining

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Standalone methacrylated extracellular matrix for digital light processing bioprinting: a practical workflow

doi: 10.3389/fbioe.2026.1774476

Figure Lengend Snippet: 3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers (CD10, CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.

Article Snippet: Specifically, rabbit anti-human CD10 (Bioss, Cat. No. BS-0527R-20; RID: AB_10854297) and rabbit anti-human vimentin (Bioss, Cat. No. BS-0756R-20; RRID: AB_10855343) were used as primary antibodies, with a rabbit IgG isotype control (Santa Cruz Biotechnology, Cat. No. sc-8306; RRID: AB_653100).

Techniques: Cell Attachment Assay, Cell Culture, Staining, Negative Control

Journal: Future Science OA

Article Title: Phosphoglucose isomerase directs the inflammatory response, calcium influx and fibroblast migration in keloids

doi: 10.1080/20565623.2026.2615968

Figure Lengend Snippet: PGI expression was increased in hyperfibrotic regions in keloid tissues. (A) Immunohistochemical staining for PGI in normal skin and keloids (original magnification 40). Right panels are high-power views of the tissues (original magnification 200). The black rectangles in the left panels indicate the areas enlarged at high magnification, respectively. The PGI intensity is shown (B). (C) Sections of keloid tissues and normal skin were deparaffinized and further incubated with antibodies against PGI and vimentin. The expression of PGI (green) and vimentin (red) was localized in keloid tissue and normal skin (original magnification 100). Right panels are high-power views of tissues, identifying colocalization of PGI (green) and vimentin (red) in keloid and normal skin (original magnification 200). The white rectangles in the left panels show the enlarged areas at high magnification, respectively. The number of PGI-positive, vimentin-expressing cells was quantified from five randomly selected high-power fields. The percentage of these cells normalized to total cells (DAPI-stained cells) in the hypercellular areas is shown (D). Data are presented as the mean ± SD. (** p < 0.01) from representative data of 3 independent experiments.

Article Snippet: Sections were applied with 1:100-diluted rabbit anti-human PGI (#57893, Cell Signaling) and 1:500-diluted mouse anti-human vimentin primary antibodies (#5741, Cell Signaling) at 4 °C overnight followed by washing and incubated with secondary antibodies conjugated with 1:500-diluted goat anti-mouse Alexa Fluor TM 488 (A11001, Invitrogen) and goat anti-rabbit Alexa Fluor TM 568 (A11011, Invitrogen).

Techniques: Expressing, Immunohistochemical staining, Staining, Incubation